439 related articles for article (PubMed ID: 15901588)
1. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
McKenney JM
Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
5. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
7. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
[TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
Kendrach MG; Kelly-Freeman M
Ann Pharmacother; 2004; 38(7-8):1286-92. PubMed ID: 15187217
[TBL] [Abstract][Full Text] [Related]
10. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
12. Review of efficacy of rosuvastatin 5 mg.
Teramoto T; Watkins C
Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin: efficacy, safety and clinical effectiveness.
Soran H; Durrington P
Expert Opin Pharmacother; 2008 Aug; 9(12):2145-60. PubMed ID: 18671469
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
16. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
17. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
19. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]